Tiffany Chen1, Grace Kim2, Yekta Rahimi3, Monisha Kamdar4, Eduardo Fernandez-Hernandez4, Karrune Woan4, Eric L. Tam4,*, George Yaghmour4
Oncology Research, Vol.34, No.3, 2026, DOI:10.32604/or.2025.072443
- 24 February 2026
Abstract Acute myeloid leukemia (AML) remains a biologically heterogeneous disease with historically limited targeted therapies and poor outcomes. The development of menin inhibitors represents a promising shift, particularly for patients harboring KMT2A rearrangements (KMT2Ar) and NPM1 mutations (NPM1m). This manuscript reviews the molecular rationale of menin inhibition for aberrant homeobox/myeloid ectopic insertion site 1 (HOX/MEIS1)-driven gene expression and leukemogenesis, clinical trial outcomes, and safety data for menin inhibitors, with a focus on recently FDA-approved revumenib and several other agents in development, ziftomenib (KO-539), bleximenib (JNJ-75276617), and icovamenib (BMF-219). We also focused our discussion on future directions to include More >